Pharmaceutical & Biopharma
It is estimated that pharma companies put an average of 8.5 compounds into clinical development to get one approval. Of those candidates that fail, approximately 30% are rejected because of pharmacokinetic-related failures (pharmacokinetics is concerned with the movement of drugs within the body).
This redundancy in effort and money can be significantly reduced if pharmacokinetic parameters are better understood earlier in pharmaceutical development. Our instruments do just this: providing *in vivo-*level **insights in vitro.
The cornerstone of candidate selection and optimization lies in clinical pharmacokinetics during drug development: the study of the relationship between the drug dose–exposure-response in the body.
Our instruments are used for this study, specifically the liberation of the drug from its dosage form and the absorption of drug products into the blood. The majority of pharmacokinetic studies occur in pharma and biopharma.